Clinical Trial

French Registry of First-line Treatment of Acute Promyelocytic Leukemia

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options, clinical effectiveness and cost-effectiveness, long-term outcome, and short- and long-term toxic effects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2016-10-17.
Status change: Recruiting → Active, Not Recruiting 2025-12-04
Trial Details
NCT Number NCT02938858
Lead Sponsor Groupe Francophone des Myelodysplasies
Collaborators: Teva Pharmaceuticals USA
Conditions Acute Promyelocytic Leukemia
Enrollment 400 participants
Start Date 2015-10
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-11